Like pls. Anyone_老虎社区_美港股上老虎

amazingjscy
2021-08-13

Like pls. Anyone

F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients<blockquote>F-star 的 FS118 开发计划将纳入检查点初治癌症患者</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":894979918,"tweetId":"894979918","gmtCreate":1628786476934,"gmtModify":1633689480419,"author":{"id":3581817944555537,"idStr":"3581817944555537","authorId":3581817944555537,"authorIdStr":"3581817944555537","name":"amazingjscy","avatar":"https://static.tigerbbs.com/3632de3d207a0a0bd5bb77d1daaf74ef","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Like pls. Anyone</p></body></html>","htmlText":"<html><head></head><body><p>Like pls. Anyone</p></body></html>","text":"Like pls. Anyone","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/894979918","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=zh_CN&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients<blockquote>F-star 的 FS118 开发计划将纳入检查点初治癌症患者</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<p><ul>  <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>  <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>  <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>  <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>  <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>  <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li> </ul></p><p><blockquote><ul><li><b>F-star 治疗公司</b>（纳斯达克股票代码：FSTX）已将 FS118 的临床开发策略扩展到检查点抑制剂初治患者。</li><li>这项新研究将于2021年2月开始，包括非小细胞肺癌（NSCLC）和弥漫性大B细胞淋巴瘤（DLBCL）患者的生物标志物富集亚组。</li><li>FS118是靶向LAG-3和PD-L1的双特异性抗体。</li><li>除了扩大的FS118临床策略外，F-star还有其他三个正在进行的项目。</li><li>F-Star 本季度末的现金和现金等价物为 8,160 万美元。</li><li><b>价格行为：</b>周四最后一次检查时，FSTX 股价在市场时段上涨 4.92%，至 6.93 美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients<blockquote>F-star 的 FS118 开发计划将纳入检查点初治癌症患者</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients<blockquote>F-star 的 FS118 开发计划将纳入检查点初治癌症患者</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-08-12 23:12</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><ul>  <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>  <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>  <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>  <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>  <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>  <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li> </ul></p><p><blockquote><ul><li><b>F-star 治疗公司</b>（纳斯达克股票代码：FSTX）已将 FS118 的临床开发策略扩展到检查点抑制剂初治患者。</li><li>这项新研究将于2021年2月开始，包括非小细胞肺癌（NSCLC）和弥漫性大B细胞淋巴瘤（DLBCL）患者的生物标志物富集亚组。</li><li>FS118是靶向LAG-3和PD-L1的双特异性抗体。</li><li>除了扩大的FS118临床策略外，F-star还有其他三个正在进行的项目。</li><li>F-Star 本季度末的现金和现金等价物为 8,160 万美元。</li><li><b>价格行为：</b>周四最后一次检查时，FSTX 股价在市场时段上涨 4.92%，至 6.93 美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1,"symbols_score_info":{"FSTX":0.9}},"isVote":1,"tweetType":1,"viewCount":1774,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients<blockquote>F-star 的 FS118 开发计划将纳入检查点初治癌症患者</blockquote>

评论（3）

热议股票